ADENOVIRUS BASED P53 GENE THERAPY FOR OVARIAN CANCER

描述：(申请人摘要) 该应用程序的目标是开发一种临床前治疗方法 用腺病毒载体编码的卵巢癌模型 人类P53肿瘤抑制基因。此应用程序涉及 导入具有直接或间接肿瘤细胞毒性的基因 肿瘤生长抑制功能(通过一种称为 “旁观者效应”)，或者可能两者兼而有之。申请人已证明 用腺病毒载体进行体内基因治疗的疗效 将具有生物活性的p53基因转移到卵巢癌细胞。目标是 这个项目的目的是进一步明确以下五个方面的内容 腺病毒载体p53基因治疗卵巢癌的临床研究 首先，虽然p53基因疗法在显微镜下显示出了疗效 疾病模型，申请人计划确定这种治疗方法是否 在存在更大的肿瘤体积时会更有效 近距离模拟人类卵巢癌。第二，因为突变型P53蛋白 可以抑制野生型P53的功能，他计划研究其作用 内源性P53基因突变对腺病毒载体免疫应答的影响 P53基因治疗。这些结果可能使他能够预测患者 对P53基因治疗的反应。第三，他将确定机制 P53通过其作用抑制G2期肿瘤的生长。这是有据可查的 将野生型p53基因导入癌细胞系会导致 G1级被捕。然而，他最近观察到，某些细胞会阻止 在G2/M检查站。DNA合成过程中细胞的停滞和 DNA损伤后的复制被认为为细胞提供了 有足够的时间修复损伤，然后才能进入细胞 周而复始。第四，因为P53已被证明能使化疗再敏感。 耐受烷化剂的细胞，他计划确定 腺病毒载体P53基因单独或联合治疗的疗效 联合顺铂治疗。最后，一些数据表明， 野生型p53调节强大的血管生成和抗血管生成之间的平衡 血管生成因子。因此，他计划研究旁观者效应 腺病毒为基础的p53基因治疗对肿瘤血管生成的影响。在这 申请，他打算迈出翻译的第一步 一种基于腺病毒的癌症基因的有希望的初步数据 实用化、科学化的人体治疗模式体系 审判。

DESCRIPTION: (Applicant's Abstract) The goal of this application is to develop a preclinical therapeutic model of ovarian cancer involving an adenovirus-based vector encoding the human p53 tumor suppressor gene. This application involves the introduction of a gene that has direct tumor cytotoxicity or indirect tumor growth inhibitory function (through a phenomenon termed the "bystander effect"), or potentially both. The applicant has demonstrated the efficacy of gene therapy in vivo using an adenovirus vector for the transfer of biologically active p53 into ovarian cancer cells. The goal of this project is to further define the following five aspects of adenovirus-based p53 gene therapy in the treatment of ovarian cancer. First, while p53 gene therapy has shown efficacy in a microscopic disease model, the applicant plans to determine whether this treatment will be effective in the presence of larger tumor volumes that more closely model human ovarian cancer. Second, because mutant p53 protein can inhibit wild type p53 function, he plans to investigate the role of specific endogenous p53 mutations on the response to adenovirus-based p53 gene therapy. These results may allow him to predict patient response to p53 gene therapy. Third, he will determine the mechanisms by which p53 acts to inhibit tumor growth in G2. It is well documented that introduction of cancer cell lines with wild-type p53 results in a G1 arrest. However, he has recently observed that certain cells arrest at the G2/M checkpoint. The arrest of cells during DNA synthesis and replication after DNA damage is thought to provide the cell with sufficient time to repair the damage before progression through the cell cycle. Fourth, because p53 has been shown to re-sensitize chemo- resistant cells to alkylating agents, he plans to determine the effectiveness of adenovirus-based p53 gene therapy alone or in combination with cisplatin therapy. Finally, some data suggest that wild-type p53 regulates a balance of potent angiogenic and anti- angiogenic factors. Thus, he plans to investigate the bystander effect of adenovirus-based p53 gene therapy on tumor angiogenesis. In this application, he intends to take the first steps toward the translation of promising preliminary data on an adenovirus-based cancer gene therapeutic model system into practical and scientifically based human trials.